# ETON PHARMACEUTICALS, INC. (ETON) · Edgar & Edgarette company card

> Eton Pharmaceuticals (ETON) grew revenue 105% in FY2025 to $80 million, operating margin -1.1% against a -3.8% median for pharmaceutical preparations, equity 28.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1710340 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ETON) · [JSON](https://www.pops4.com/boards/company/ETON.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $80M |
| Revenue growth, 1 year | 104.9% |
| Revenue growth per year | 38.3% |
| Operating margin | -1.1% (prior year -6.7%) |
| Net margin | -5.8% |
| Operating cash flow | $11M |
| Capital spending | $333,000 |
| Free cash flow | $10M |
| Cash | $26M |
| Long-term debt | $31M |
| Total assets | $92M |
| Total equity | $26M |
| Equity ÷ assets | 28.4% |
| Return on equity | -17.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.05 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -1.1% in FY2025; revenue is hard to predict: its 80% range is ±50%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $80.0M (FY2025), total debt $30.6M. Experience: revenue up 104.9% on the year, up 38.3% a year over 4 years; operating margin -1.1%, up from -6.7%. Soundness: equity 28.4% of assets, return on equity -17.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $80.0M and $239.7M next year (method v4.1: its own 4-year record of growth weighed at 50% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $83.4M to $230.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1.1% against a -3.8% median; growth 104.9% against 13.7%.

Range logged 2026-10-15, receipt b9d63b2900927987, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-08-04 ([filing](https://www.sec.gov/Archives/edgar/data/1710340/000143774926025506/0001437749-26-025506-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000009/0001710340-26-000009-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/0001710340-26-000006-index.htm)
- 8-K · filed 2026-11-05 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000143774926035258/0001437749-26-035258-index.htm)
- 8-K · filed 2026-11-02 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000143774926034277/0001437749-26-034277-index.htm)
- 8-K · filed 2026-10-14 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000143774926032600/0001437749-26-032600-index.htm)
- 8-K · filed 2026-09-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/0001437749-26-031281-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001710340.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1710340

## Cite

POPS4, Edgar & Edgarette: ETON PHARMACEUTICALS, INC. (ETON) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ETON. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

